You're absolutely right. At least it's a ginger start to get out of that 100 year old amyloid cave. That's why it's so exciting that AVXL uses genome sequencing to get a better understanding of the genetic make-up of the type of dementias they are treating ib their studies. AD or maybe even all dementias need to be much better understood/classified on a neurophysiological and molecular level for a correct diagnosis and proper treatment.